The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 30 March 2026•Updated 30 March 2026•

1 min read

Blackstone Closes $6.3 Billion Life Sciences Fund to Drive Biotech Innovation

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Blackstone closed a new $6.3 billion life sciences fund.

2 months ago

Version History

1 additional source confirmed this story

Version 12 months ago

What changed: The update highlights that the $6.3 billion fund is the largest ever in the sector and 40% larger than the previous fund, while noting the BXLS platform's total AUM reached $15 billion with major pharmaceutical partnerships.

Blackstone has successfully closed its latest life sciences fund at $6.3 billion, marking the largest fund ever raised in this sector. This new vehicle is nearly 40% larger than Blackstone's predecessor fund, reflecting a significant expansion in the firm's biopharmaceutical investment strategy. With this close, the Blackstone Life Sciences (BXLS) platform now manages a total of $15 billion in assets. The platform has recently secured high-profile deals and partnerships with industry leaders such as Teva Pharmaceutical, Merck & Co., and Johnson & Johnson. These capital commitments are designed to accelerate research, development, and clinical advancements for companies at various growth stages. Analysts view this record-breaking raise as a major milestone for Blackstone's assets under management (AUM) and the broader global biotech industry.